Oncogenic Signaling Pathways and Pathway-Based Therapeutic Biomarkers in Lymphoid Malignancies.

Journal Article (Journal Article;Review)

Lymphoma is characterized by heterogeneous biology, pathologic features, and clinical outcome. This has been proven by accumulating pathologic and molecular evidence attributed to underlying aberrant alterations at genetic, epigenetic, transcriptional, protein, microenvironmental levels, and dysregulated oncogenic signaling pathways. In the era of precision medicine, targeting oncogenic pathways to design drugs and to optimize treatment regimens for the lymphoma patients is feasible and clinically significant. As such, further understanding of the biology and the mechanisms behind lymphoma development and identification of oncogenic pathway activation and pathway-based biomarkers to better design precise therapies are challenging but hopeful. Furthermore, pathway-based targeted therapies in combination with traditional chemotherapy, single specific targeted antibody therapy, and immunotherapy might raise the hope for the patients with lymphoma, especially for relapsed and refractory lymphoma patients.

Full Text

Duke Authors

Cited Authors

  • Sun, R; Wang, J; Young, KH

Published Date

  • 2017

Published In

Volume / Issue

  • 22 / 5-6

Start / End Page

  • 527 - 557

PubMed ID

  • 29604930

Pubmed Central ID

  • PMC5961736

International Standard Serial Number (ISSN)

  • 0893-9675

Digital Object Identifier (DOI)

  • 10.1615/CritRevOncog.2017020816


  • eng

Conference Location

  • United States